NEW YORK (GenomeWeb News) – UK molecular diagnostics firm Lumora today announced a supply agreement with Promega for use of its luciferase in Lumora's Bioluminescent Assay in Real-Time, or BART, technology.
The deal is the first commercial molecular diagnostic application for Promega's Ultra-Glo luciferase, Lumora said. Its BART technology, a novel reporter system, is used with isothermal nucleic acid amplification technology and causes a sample to light up when a diagnostic test result is positive.
Financial and other terms of the deal were not disclosed.
"Matthew Cook, head of commercial sales for Promega, said that Lumora has "some excellent technologies in the molecular diagnostics space, which combined with Ultra-Glo has the potential to open new markets."